Search
Sarepta Therapeutics Inc
SRPTAdd to Watchlist
14.860USD
-0.700-4.50%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.57BMarket Cap
23.85P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Sarepta Therapeutics Inc is 6.59, ranking 128 out of 155 in the Pharmaceuticals industry. The average price target is 17.50, with a high of 185.00 and a low of 5.00.
Analyst Rating
Based on
27
analysts
Hold
Current Rating
22.593
Target Price
+52.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Sarepta Therapeutics Inc
SRPT
27
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Sarepta Therapeutics Inc's expected revenue for the next quarter?
Sarepta Therapeutics Inc's expected revenue is 364.34M.
What is Sarepta Therapeutics Inc's price target?
Analysts forecast that Sarepta Therapeutics Inc's price target is USD 17.50, with the highest forecast at USD 185.00 and the lowest forecast at USD 5.00.
How have Sarepta Therapeutics IncSRPT's recent earnings per share performed?
The market expectation was USD 3.15, while Sarepta Therapeutics IncSRPT's earnings per share (EPS) for the previous quarter was USD -2.70. EPS for the next quarter is expected at USD 0.26.
What is the analyst rating for Sarepta Therapeutics Inc?
Based on the ratings of Sarepta Therapeutics Inc's stock from 27 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.